Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02835976
A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Anti-EGFR-Containing RegimenDrug: Bevacizumab-containing regimenDrug: Chemotherapy
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4278
- Registration Number
- NCT02831842
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT02828930
- Locations
- 🇭🇺
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
- Conditions
- Malignant MelanomaChronic Myelogenous LeukemiaRenal Cell Carcinoma
- Interventions
- Drug: Recombinant Interferon Alfa 2a
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT02829775
A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT02827266
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT02825940
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT02824055
- Locations
- 🇺🇸
CNS Network, Garden Grove, California, United States
🇺🇸St Louis Clinical Trials, Saint Louis, Missouri, United States
🇺🇸Parexel California Clinical Trials Medical Group, Glendale, California, United States
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
- Conditions
- Castrate-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02814669
- Locations
- 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 565
- Registration Number
- NCT02813785
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Affiliated Hospital of Bengbu Medical College, Bengbu, China
Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 850
- Registration Number
- NCT02809833